|
|
|
International Clinical Trials
|
Clinical trials require the management of more data than ever before, but many of the tools available on the market have prodigious shortcomings in both this and safety. Sponsors and CROs struggle to collect, synthesise and analyse information from myriad siloed sources, which affects their understanding of drug safety and slows data reconciliation for submission. An alternative approach to data integration could power the next generation of clinical innovation by bridging the functional and structural gaps between information management and pharmacovigilance (PV).
Regulatory agencies are concerned about trial data quality and patient safety. The recent emphasis on risk management in the latest ICH E6 (R2) guidelines makes it clear that there is significant work to do in removing the barriers to data review, quality oversight and safety monitoring. Both sponsors and CROs rely on an increasing number of systems and datasets to manage complex and often decentralised clinical studies. Their data are often siloed, which makes obtaining a holistic picture of the trial challenging.
Most data management solutions on the market today are inflexible and fall short in their ability to power the solutions needed to best manage clinical research, particularly as they pertain to timely interfaces with PV. All PV systems will ultimately provide information in the E2B format as required, but data structures from clinical data management systems (CDMS) vary, and conversion to study data tabulation models or other formats can delay key deliverables for holistic study risk and safety management.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Digitalisation solutions for a connected plant: Bridging the gap for Pharma 4.0
Digitalisation solutions for a connected plant: Bridging the gap for
Pharma 4.0 Digital transformation is key in ensuring the flexibility,
resilience and agility required in pharmaceutical manufacturing, but
traditionally, the industry has been resistant to digitalisation. Now,
regulatory bodies are pushing for manufacturers to embrace Pharma 4.0
and to incorporate automation into their operations. Here, Alexandra
Hughes, Industry Sales Manager at automation software supplier,
COPA-DATA UK, explains how its zenon automation integration layer (AIL)
can support the digital transformation of pharmaceutical manufacturing
and bridge the gap between brownfield and greenfield equipment.
More info >> |
|
 |
White Papers |
 |
|
R&D to Product: How to Reduce Costly Scale-Up Problems
Natoli Engineering Company, Inc.
When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scaleup and performance of the formulation at production levels. Problems with capping/lamination and sticking/ picking are often first realized when a formulation is introduced to a level of compression required to supply market demand.
More info >> |
|
|
